Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Efficacy and Tolerance of Isatuximab, Cyclophosphamide, Bortezomib, and Dexamethasone (Isa-CBD) Induction Chemotherapy in Newly Diagnosed, Transplant Eligible Multiple Myeloma: Report of the Phase 2 Multi-Centre, Open Label Canadian Myeloma Research Group (CMRG)-008 Prospective Clinical Trial

Rami Kotb, Darrell White, Sita Bhella, Arleigh McCurdy, Irwindeep Sandhu, Hira Mian, Julie Stakiw, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Donna Reece

Blood (2023) 142 (Supplement 1): 4751.

https://doi.org/10.1182/blood-2023-190168

Published: 2023

Journal Articles

Preclinical and Translational Biomarker Analyses to Inform Clinical Development of Mezigdomide (CC-92480) in Combination with Dexamethasone and Daratumumab in Multiple Myeloma

Tracy T. Chow, Michael Amatangelo, Peilin Ma, Chad C. Bjorklund, Krista Wollerman, Tiziana Civardi, Phillip Koo, Yue Zhu, Paulo Maciag, Jessica Katz, Aparna Raval, Albert Oriol, Robert Z. Orlowski, Darrell White, Paul G. Richardson, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 3318.

https://doi.org/10.1182/blood-2023-178881

Published: 2023

Journal Articles

Prevention of Ocular Toxicity Using Protective Contact Lenses in Multiple Myeloma Patients Receiving Belantamab Mafodotin, Pomalidomide and Dexamethasone: A Sub-Study of the Cmrg-007 Trial

Martha L Louzada, Donna E. Reece, Arleigh McCurdy, Rami Kotb, Ibraheem Othman, Hira Mian, Toni Lin, Michael P Chu, Darrell White, Stephen Parkin, Engin Gul, Aniba Khan, Suzanne Trudel

Blood (2023) 142 (Supplement 1): 4756.

https://doi.org/10.1182/blood-2023-174993

Published: 2023

Journal Articles

Disease Characteristics and Outcomes of 504 Young Patients Diagnosed with Multiple Myeloma Treated with Modern Therapies in Canada

Blood (2023) 142 (Supplement 1): 1954.

https://doi.org/10.1182/blood-2023-174338

Published: 2023

Journal Articles

Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial

Paul G. Richardson, Irwindeep Sandhu, Craig C. Hofmeister, Robert Z. Orlowski, Darrell White, Angelo Belotti, Charlotte Toftmann Hansen, Noopur S. Raje, Tracy T. Chow, Zehua Zhou, Tiziana Civardi, Phillip Koo, Yue Zhu, Jessica Katz, Albert Oriol

Blood (2023) 142 (Supplement 1): 1013.

https://doi.org/10.1182/blood-2023-174443

Published: 2023

Journal Articles

Second Line Treatment and Outcomes of Patients with Multiple Myeloma: A Real World Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Arleigh McCurdy, Engin Gul, Donna Reece, Christopher P. Venner, Darrell White, Jiandong Su, Michael P. Chu, Victor H. Jimenez-Zepeda, Kevin Song, Hira Mian, Michael Sebag, Debra Bergstrom, Julie Stakiw, Anthony Reiman, Rami Kotb, Muhammad Aslam, Rayan Kaedbey, Martha L Louzada, Richard LeBlanc

Blood (2023) 142 (Supplement 1): 3364.

https://doi.org/10.1182/blood-2023-181138

Published: 2023

Journal Articles

Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort

Sebastian Grosicki, Ulf-Henrik Mellqvist, Łukasz Pruchniewski, Jacob Crafoord, Suzanne Trudel, Chang-Ki Min, Darrell White, Adrian Alegre, Markus Hansson, Takashi Ikeda, Kazutaka Sunami, Eric Leip, Arthur Kudla, Gregory Finn, Youngil Koh

Blood (2022) 140 (Supplement 1): 4407–4408.

https://doi.org/10.1182/blood-2022-162738

Published: 2022

Journal Articles

Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial

Sagar Lonial, Al-Ola Abdallah, Faiz Anwer, Ashraf Z. Badros, Manisha Bhutani, Abdullah Khan, Brea Lipe, Albert Oriol, Darrell White, Michael Amatangelo, Kexin Jin, Mark Masin, Vi Nguyen, Alpesh Amin, Paulo Maciag, Niels WCJ Van De Donk

Blood (2022) 140 (Supplement 1): 4398–4400.

https://doi.org/10.1182/blood-2022-158180

Published: 2022

Journal Articles

Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Blood (2022) 140 (Supplement 1): 4287–4289.

https://doi.org/10.1182/blood-2022-168843

Published: 2022

Journal Articles

Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Blood (2022) 140 (Supplement 1): 289–291.

https://doi.org/10.1182/blood-2022-158219

Published: 2022

Journal Articles

Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment

Blood (2021) 138 (Supplement 1): 2751.

https://doi.org/10.1182/blood-2021-150998

Published: 2021

Journal Articles

CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002

Blood (2021) 138 (Supplement 1): 2731.

https://doi.org/10.1182/blood-2021-147812

Published: 2021

Journal Articles

Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial

Blood (2021) 138 (Supplement 1): 2733.

https://doi.org/10.1182/blood-2021-148481

Published: 2021

Journal Articles

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Nizar J. Bahlis, Heather Sutherland, Darrell White, Michael Sebag, Suzanne Lentzsch, Rami Kotb, Christopher P. Venner, Cristina Gasparetto, Aldo Del Col, Paola Neri, Donna Reece, Michael Kauffman, Sharon Shacham, T. J. Unger, Jacqueline Jeha, Jean-Richard Saint-Martin, Jatin Shah, Christine Chen

Blood (2018) 132 (24): 2546–2554.

https://doi.org/10.1182/blood-2018-06-858852

Published: 2018

Includes: Supplemental data

Journal Articles

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Blood (2018) 131 (3): 301–310.

https://doi.org/10.1182/blood-2017-07-795047

Published: 2018

Includes: Supplemental data

Journal Articles

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux

Saad Z Usmani, MD FACP, Meletios A Dimopoulos, Andrew Belch, Darrell White, MD, Lofti Benboubker, Gordon Cook, MD PhD, Merav Leiba, MD, James Morton, MBBS, BSc(MD, FRACP, FRCPA, P. Joy Ho, Kihyun Kim, Naoki Takezako, MD PhD, Nushmia Z Khokhar, Mary Guckert, Kaida Wu, MD PhD, Xiang Qin, Tineke Casneuf, Christopher Chiu, PhD, A. Kate Sasser, Jesús San-Miguel, MD PhD

Blood (2016) 128 (22): 1151.

https://doi.org/10.1182/blood.V128.22.1151.1151

Published: 2016

Journal Articles

An Open-Label, Single-Arm, Phase 1 Study of the Pharmacokinetics (PK) and Safety of Carfilzomib in Patients with Relapsed Multiple Myeloma and End-Stage Renal Disease (ESRD)

Hang Quach, MBBS (Hons), FRACP, FRCPA, MD, Darrell White, Andrew Spencer, P. Joy Ho, Divaya Bhutani, Mike White, Sandeep Inamdar, Chris Morris, Ying Ou, Martin Gyger

Blood (2016) 128 (22): 3318.

https://doi.org/10.1182/blood.V128.22.3318.3318

Published: 2016

Journal Articles

Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

Blood (2016) 128 (22): 3330.

https://doi.org/10.1182/blood.V128.22.3330.3330

Published: 2016

Journal Articles

Final Analysis of Overall Survival from the First Trial

Blood (2016) 128 (22): 241.

https://doi.org/10.1182/blood.V128.22.241.241

Published: 2016

Journal Articles

Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial

Blood (2016) 128 (22): 977.

https://doi.org/10.1182/blood.V128.22.977.977

Published: 2016

NARROW

Efficacy and Tolerance of Isatuximab, Cyclophosphamide, Bortezomib, and Dexamethasone (Isa-CBD) Induction Chemotherapy in Newly Diagnosed, Transplant Eligible Multiple Myeloma: Report of the Phase 2 Multi-Centre, Open Label Canadian Myeloma Research Group (CMRG)-008 Prospective Clinical Trial

Preclinical and Translational Biomarker Analyses to Inform Clinical Development of Mezigdomide (CC-92480) in Combination with Dexamethasone and Daratumumab in Multiple Myeloma

Prevention of Ocular Toxicity Using Protective Contact Lenses in Multiple Myeloma Patients Receiving Belantamab Mafodotin, Pomalidomide and Dexamethasone: A Sub-Study of the Cmrg-007 Trial

Disease Characteristics and Outcomes of 504 Young Patients Diagnosed with Multiple Myeloma Treated with Modern Therapies in Canada

Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial

Second Line Treatment and Outcomes of Patients with Multiple Myeloma: A Real World Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort

Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial

Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment

CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002

Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux

An Open-Label, Single-Arm, Phase 1 Study of the Pharmacokinetics (PK) and Safety of Carfilzomib in Patients with Relapsed Multiple Myeloma and End-Stage Renal Disease (ESRD)

Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

Final Analysis of Overall Survival from the First Trial

Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only